Onconase RNase protein data

ACEL presented interim results from an ongoing Phase II trial in patients with advanced malignant mesothelioma, a cancer of the lining of the lungs, chest and abdomen often associated with asbestos exposure. Most patients die within 6-12 months.

Of 20 evaluable patients, 13 showed evidence of clinical activity and had a median survival of two years after weekly treatments with Onconase. Of the responders, 3 had partial responses and 10 had stabilization of previously progressive disease. Data were presented at the American Society of Clinical Oncology meeting in Philadelphia. ...